OlympiAD final overall survival: Olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) Meeting Abstract
| Authors: | Robson, M. E.; Im, S. A.; Senkus, E.; Xu, B.; Domchek, S.; Masuda, N.; Delaloge, S.; Li, W.; Tung, N.; Armstrong, A.; Wu, W.; Goessl, C.; Runswick, S.; Conte, P. |
| Abstract Title: | OlympiAD final overall survival: Olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) |
| Meeting Title: | 109th Annual Meeting of the American Association for Cancer Research (AACR) |
| Journal Title: | Cancer Research |
| Volume: | 78 |
| Issue: | 13 Suppl. |
| Meeting Dates: | 2018 Apr 14-18 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2018-07-01 |
| Language: | English |
| ACCESSION: | WOS:000468818900036 |
| DOI: | 10.1158/1538-7445.Am2018-ct038 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: CT038 -- Source: Wos |
